University of Oxford

Albus Health's AI-powered device detects child asthma attacks up to 5 days before onset, potentially transforming respiratory care by enabling early intervention.

Scientists discover Benralizumab, a new asthma treatment targeting eosinophils, offering a more precise approach than traditional steroids, with significant improvements in clinical trials.

Benralizumab, a monoclonal antibody, was found more effective than steroids in treating eosinophilic exacerbations of asthma and COPD, reducing hospitalizations and improving quality of life in a phase two clinical trial.

King’s College London researchers developed Benralizumab, a single injection potentially replacing steroid therapy for asthma and COPD, targeting eosinophils. In a study, it reduced treatment failure by 45% compared to 74% with steroids, improving quality of life and reducing hospital admissions. A larger trial is planned to assess cost-effectiveness.

Benralizumab injection during asthma and COPD attacks reduces need for further treatment by 30%, outperforming steroid tablets, according to a study in The Lancet Respiratory Medicine.

A new injection for asthma and COPD attacks is 30% more effective than steroid tablets, reducing the need for further treatment. The study, published in The Lancet Respiratory Medicine, found benralizumab, a monoclonal antibody, to be more effective at the point of exacerbation compared to prednisolone. This could be a significant advancement in treating eosinophilic exacerbations, which make up a significant portion of asthma attacks and COPD flare-ups.

A new asthma treatment, the first in 50 years, could be 'game-changing' for millions. The injection, benralizumab, is more effective than steroid tablets, reducing the need for further treatment by 30% and improving quality of life for asthma and COPD patients.

Nguyễn Thụy Bá Linh, from University College London, becomes the first Vietnamese scientist to win the UK's TechWomen 100 Awards for her biotechnology achievements, promoting the image of Vietnamese women in science and technology.

Harvard's eight newest Rhodes Scholars, representing diverse disciplines and countries, will pursue academic studies at Oxford University. Matthew Anzarouth focuses on Canadian federalism and multiculturalism; Lena Ashooh studies animal ethics; Shahmir Aziz aims to foster biotech startups in Pakistan; Tommy Barone investigates democratic beliefs; Sofia Corona works on sustainable transportation; Aneesh Muppidi explores AI ethics; Ayush Noori researches neuroscience and AI for neurological diseases; Laura Wegner co-founded a healthcare startup to improve patient data management.

Ultromics' EchoGo® Amyloidosis, an AI-based software-only medical device, received FDA clearance for early detection of Cardiac Amyloidosis, becoming the first device under the FDA’s Total Product Lifecycle Advisory Program to achieve marketing authorization. EchoGo® Amyloidosis, requiring only a single echocardiographic clip, enhances detection accuracy and efficiency, aiding in timely treatment for this underdiagnosed heart condition.